SMYD2 is highly expressed in pediatric acute lymphoblastic leukemia and constitutes a bad prognostic factor
| Autor: | Fabio Pittella Silva, Andrea Barretto Motoyama, Maria Sueli Soares Felipe, Rosangela Vieira Andrade, Luis Henrique Toshihiro Sakamoto |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Prognostic factor Protein family Adolescent medicine.medical_treatment Antineoplastic Agents Biomarkers Pharmacological Pediatric Acute Lymphoblastic Leukemia Internal medicine Gene expression Biomarkers Tumor Medicine Humans Child Chemotherapy business.industry Gene Expression Regulation Leukemic Infant Hematology Methylation Histone-Lysine N-Methyltransferase Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Survival Analysis Up-Regulation Quantitative Real Time PCR medicine.anatomical_structure Case-Control Studies Child Preschool Immunology Female Bone marrow business |
| Zdroj: | Leukemia research. 38(4) |
| ISSN: | 1873-5835 |
| Popis: | Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy. Although several clinical characteristics can be associated with worse prognosis, more robust biological markers still remains uncovered. SMYD2, a member of SMYD protein family, regulates the activity of several proteins through methylation. In this study, we performed quantitative real time PCR to compare the expression of SMYD2 in 83 pediatric ALL patients and non-neoplastic bone marrow samples (BMS). The study revealed that SMYD2 expression is altered in ALL BMS and its high expression was correlated with a bad prognosis. Moreover, we also revealed that SMYD2 expression level significantly decreases in patients that respond to chemotherapy treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect